Comparison of complete renal response and mortality in early- and late-onset lupus nephritis: A multicenter retrospective study of a Japanese cohort
Background: Most patients with systemic lupus erythematosus (SLE) progress to lupus nephritis (LN) within 5 years of their SLE diagnosis, although it is not uncommon for LN to develop at later time points. Here we evaluated the clinical features of early- and late-onset LN.
Patients and Methods: We retrospectively analyzed the cases of 184 of the 201 patients who underwent a renal biopsy at Nagasaki University Hospital and associated community hospitals between 1990 and 2016 and were diagnosed as having LN. Early-onset was defined as the development of LN within the first 5 years after the patient's SLE diagnosis, and late-onset was defined as LN development >5 years post-diagnosis. We analyzed the complete renal response (CR) at 6 and 12 months after induction therapy, the classification of renal pathology, and the mortality of the early- and late-onset LN groups.
Results: The mean follow-up duration after renal biopsy was 123±85 months. There were 113 (61.4%) early-onset patients and 71 (38.6%) late-onset patients. A multivariate analysis revealed that the following factors were predictive of CR. At 6 months: female sex (odds ratio [OR] 4.64, 95% confidence interval [CI] 1.66–12.98, p=0.002), proteinuria (OR 0.82, 95%CI 0.70–0.95, p=0.003), index of activity (0–24) (OR 0.85, 95%CI 0.74–0.97, p=0.014), and early-onset LN (OR 2.26, 95%CI 1.11–4.58, p=0.023). At 12 months: female sex (OR 3.95, 95% CI 1.62–9.64, p=0.002), index of activity (0–24) (OR 0.80, 95%CI 0.71–0.91, p<0.001), and early-onset LN (OR 1.98, 95%CI 1.04–3.79, p=0.038). In a Cox proportional hazards model, the early-onset LN group had a significantly better mortality rate than the late-onset LN group (p=0.038).
Conclusions: In our cohort, early-onset LN was a better predictor of CR at 6 and 12 months. Our results suggest that early-onset LN patients had lower mortality than late-onset LN patients.
Figure 1
Figure 2
Figure 3
This is a list of supplementary files associated with this preprint. Click to download.
Posted 13 Jun, 2020
On 22 Jul, 2020
On 12 Jun, 2020
On 12 Jun, 2020
Invitations sent on 12 Jun, 2020
On 11 Jun, 2020
On 11 Jun, 2020
On 31 May, 2020
Received 25 May, 2020
On 18 May, 2020
On 14 May, 2020
Invitations sent on 14 May, 2020
On 13 May, 2020
On 13 May, 2020
On 13 May, 2020
Comparison of complete renal response and mortality in early- and late-onset lupus nephritis: A multicenter retrospective study of a Japanese cohort
Posted 13 Jun, 2020
On 22 Jul, 2020
On 12 Jun, 2020
On 12 Jun, 2020
Invitations sent on 12 Jun, 2020
On 11 Jun, 2020
On 11 Jun, 2020
On 31 May, 2020
Received 25 May, 2020
On 18 May, 2020
On 14 May, 2020
Invitations sent on 14 May, 2020
On 13 May, 2020
On 13 May, 2020
On 13 May, 2020
Background: Most patients with systemic lupus erythematosus (SLE) progress to lupus nephritis (LN) within 5 years of their SLE diagnosis, although it is not uncommon for LN to develop at later time points. Here we evaluated the clinical features of early- and late-onset LN.
Patients and Methods: We retrospectively analyzed the cases of 184 of the 201 patients who underwent a renal biopsy at Nagasaki University Hospital and associated community hospitals between 1990 and 2016 and were diagnosed as having LN. Early-onset was defined as the development of LN within the first 5 years after the patient's SLE diagnosis, and late-onset was defined as LN development >5 years post-diagnosis. We analyzed the complete renal response (CR) at 6 and 12 months after induction therapy, the classification of renal pathology, and the mortality of the early- and late-onset LN groups.
Results: The mean follow-up duration after renal biopsy was 123±85 months. There were 113 (61.4%) early-onset patients and 71 (38.6%) late-onset patients. A multivariate analysis revealed that the following factors were predictive of CR. At 6 months: female sex (odds ratio [OR] 4.64, 95% confidence interval [CI] 1.66–12.98, p=0.002), proteinuria (OR 0.82, 95%CI 0.70–0.95, p=0.003), index of activity (0–24) (OR 0.85, 95%CI 0.74–0.97, p=0.014), and early-onset LN (OR 2.26, 95%CI 1.11–4.58, p=0.023). At 12 months: female sex (OR 3.95, 95% CI 1.62–9.64, p=0.002), index of activity (0–24) (OR 0.80, 95%CI 0.71–0.91, p<0.001), and early-onset LN (OR 1.98, 95%CI 1.04–3.79, p=0.038). In a Cox proportional hazards model, the early-onset LN group had a significantly better mortality rate than the late-onset LN group (p=0.038).
Conclusions: In our cohort, early-onset LN was a better predictor of CR at 6 and 12 months. Our results suggest that early-onset LN patients had lower mortality than late-onset LN patients.
Figure 1
Figure 2
Figure 3